CANDIDATE | FORMAT | INDICATION | RESEARCH | LEAD OPTIMIZATION | NON-CLINICAL RESEARCH | CLINICAL RESEARCH |
| FBT-N101 | MDM2 inhibitor (small molecule) | Dry AMD |  |  |  | |
| FBT-SP101 | ROS inducer (small molecule) | Dry AMD | |  |  | |
| FBT-N101 + Eylea | MDM2 inhibitor + Anti-VEGF | Wet AMD | |
CANDIDATE | FORMAT | INDICATION | RESEARCH | LEAD OPTIMIZATION | NON-CLINICAL RESEARCH | CLINICAL RESEARCH |
| FBT-N401 | YAP activating small molecule | Dry AMD Wet AMD | |
CANDIDATE | FORMAT | INDICATION | RESEARCH | LEAD OPTIMIZATION | NON-CLINICAL RESEARCH | CLINICAL RESEARCH |
| FBT-HR2-ProNP | (Recombinant protein + chemical combined) | Cancer | | |||
| FBT-ER-ProNP | (Recombinant protein + chemical combined) | Cancer | |
